Corcept Therapeutics Incorporated

22.76-0.1800-0.78%Vol 409.96K1Y Perf 89.08%
Apr 16th, 2021 16:00 DELAYED
BID22.31 ASK26.19
Open23.13 Previous Close22.94
Pre-Market- After-Market22.76
 - -  - -%
Target Price
27.00 
Analyst Rating
Moderate Buy 2.17
Potential %
18.63 
Finscreener Ranking
★★★★★     62.20
Insiders Trans % 3/6/12 mo.
-100/10/-7 
Value Ranking
★★★★★     64.59
Insiders Value % 3/6/12 mo.
-100/-74/-66 
Growth Ranking
★★★★★     82.11
Insiders Shares Cnt. % 3/6/12 mo.
-100/-64/-52 
Income Ranking
 —    -
Market Cap2.67B 
Earnings Rating
Strong Buy
Price Range Ratio 52W %
56.31 
Earnings Date
3rd May 2021

Today's Price Range

22.4223.16

52W Range

11.9131.18

5 Year PE Ratio Range

-46.00297.40

Summary:

Sell

Technical Indicators: Sell
Moving Averages: Strong Sell
Performance
1 Week
0.35%
1 Month
-11.47%
3 Months
-19.12%
6 Months
26.44%
1 Year
89.08%
3 Years
29.47%
5 Years
364.49%
10 Years
426.85%

TickerPriceChg.Chg.%
CORT22.76-0.1800-0.78
AAPL134.16-0.3400-0.25
GOOG2 297.761.10000.05
MSFT260.741.24000.48
XOM56.66-0.3200-0.56
WFC43.841.60003.79
JNJ162.241.85001.15
FB306.18-1.6400-0.53
GE13.39-0.1600-1.18
JPM153.301.13000.74
Financial StrengthValueIndustryS&P 500US Markets
9.80
10.10
0.00
0.00
-
Leverage Ratio 1.10
ProfitabilityValueIndustryS&P 500US Markets
98.40
37.30
37.90
31.00
29.01
RevenueValueIndustryS&P 500US Markets
260.63M
2.22
23.07
47.62
Earnings HistoryEstimateReportedSurprise %
Q04 20200.200.200.00
Q03 20200.210.17-19.05
Q02 20200.200.2315.00
Q01 20200.210.2519.05
Q04 20190.240.240.00
Q03 20190.190.2215.79
Q02 20190.180.17-5.56
Q01 20190.180.15-16.67
Earnings Per EndEstimateRevision %Trend
3/2021 QR0.2131.25Positive
6/2021 QR0.2538.89Positive
12/2021 FY0.997.61Positive
12/2022 FY1.2313.89Positive
Next Report Date3rd May 2021
Estimated EPS Next Report0.21
Estimates Count2
EPS Growth Next 5 Years %11.60
Volume Overview
Volume409.96K
Shares Outstanding117.31M
Trades Count4.06K
Dollar Volume32.55M
Avg. Volume571.09K
Avg. Weekly Volume315.37K
Avg. Monthly Volume494.09K
Avg. Quarterly Volume563.16K

Corcept Therapeutics Incorporated (NASDAQ: CORT) stock closed at 22.76 per share at the end of the most recent trading day (a -0.78% change compared to the prior day closing price) with a volume of 412.99K shares and market capitalization of 2.67B. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 236 people. Corcept Therapeutics Incorporated CEO is Joseph K. Belanoff.

The one-year performance of Corcept Therapeutics Incorporated stock is 89.08%, while year-to-date (YTD) performance is -13%. CORT stock has a five-year performance of 364.49%. Its 52-week range is between 11.91 and 31.18, which gives CORT stock a 52-week price range ratio of 56.31%

Corcept Therapeutics Incorporated currently has a PE ratio of 27.00, a price-to-book (PB) ratio of 5.14, a price-to-sale (PS) ratio of 10.10, a price to cashflow ratio of 18.70, a PEG ratio of 2.32, a ROA of 20.77%, a ROC of 25.52% and a ROE of 22.86%. The company’s profit margin is 29.01%, its EBITDA margin is 37.90%, and its revenue ttm is $260.63 Million , which makes it $2.22 revenue per share.

Of the last four earnings reports from Corcept Therapeutics Incorporated, there were 2 positive earnings surprise and 1 negative earnings surprise. The company has EPS estimate of $0.21 for the next earnings report. Corcept Therapeutics Incorporated’s next earnings report date is 03rd May 2021.

The consensus rating of Wall Street analysts for Corcept Therapeutics Incorporated is Moderate Buy (2.17), with a target price of $27, which is +18.63% compared to the current price. The earnings rating for Corcept Therapeutics Incorporated stock is Strong Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Corcept Therapeutics Incorporated has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Corcept Therapeutics Incorporated has a Sell technical analysis rating based on Technical Indicators (ADX : 18.16, ATR14 : 1.02, CCI20 : -87.28, Chaikin Money Flow : -0.13, MACD : -1.29, Money Flow Index : 35.73, ROC : -3.11, RSI : 40.99, STOCH (14,3) : 25.60, STOCH RSI : 0.90, UO : 41.35, Williams %R : -74.40), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Corcept Therapeutics Incorporated in the last 12-months were: Daniel N. Swisher (Option Excercise at a value of $196 500), Daniel N. Swisher (Sold 30 000 shares of value $557 810 ), David L. Mahoney (Option Excercise at a value of $270 549), G. Charles Robb (Option Excercise at a value of $1 220 000), G. Charles Robb (Sold 115 500 shares of value $3 265 148 ), George Leonard Baker (Buy at a value of $1 443 984), George Leonard Baker (Option Excercise at a value of $208 200), George Leonard Baker (Sold 60 000 shares of value $942 120 ), Hazel Hunt (Option Excercise at a value of $198 000), Joseph Douglas Lyon (Option Excercise at a value of $697 250), Joseph Douglas Lyon (Sold 75 000 shares of value $1 956 920 ), Joseph K. Belanoff (Option Excercise at a value of $3 536 000), Sean Maduck (Option Excercise at a value of $40 760), Sean Maduck (Sold 12 389 shares of value $355 152 )

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
3 (50.00 %)
3 (50.00 %)
3 (50.00 %)
Moderate Buy
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Hold
2 (33.33 %)
2 (33.33 %)
2 (33.33 %)
Moderate Sell
1 (16.67 %)
1 (16.67 %)
1 (16.67 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingModerate Buy
2.17
Moderate Buy
2.17
Moderate Buy
2.17

Corcept Therapeutics Incorporated

Corcept Therapeutics Inc is engaged in the discovery, development, and commercialization of drugs for the treatment of severe metabolic, psychiatric and oncologic disorders by modulating the effects of cortisol.

CEO: Joseph K. Belanoff

Telephone: +1 650 327-3270

Address: 149 Commonwealth Drive, Menlo Park 94025, CA, US

Number of employees: 236

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

55%45%

Bearish Bullish

54%46%

Bearish Bullish

61%39%

News

Stocktwits